UNITED STATES
            SECURITIES AND EXCHANGE COMMISSION
                  Washington, D.C. 20549

                         FORM 10-QSB

[X]  Quarterly Report under Section 13 or 15(d) of the Securities
Exchange Act of 1934 For the quarterly period ended September 30, 2002

[ ]  Transition report under Section 13 or 15(d) of the Exchange Act
For the transition period from        to
                               -------   --------


              Commission File Number: 0-49756

                   NOVUS LABORATORIES, INC.
   ----------------------------------------------------
  (Exact name of Registrant as specified in its charter)


        Delaware                                   98-0201235
 ---------------------------                   -----------------
(State or other jurisdiction                   (I.R.S. Employer
of incorporation or organization               Identification No.)

     1255 W. Pender Street
 Vancouver, B.C., Canada  V6E 2V1          (604) 325-1987
---------------------------------      -----------------------------
(Address of principal executive       (Registrant's telephone number,
 offices)                              including area code)


                                None
  -----------------------------------------------------------------
  Former Name, Address and Fiscal Year, If Changed Since Last Report

Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.   Yes   X      No

The number of shares outstanding of the registrant's common stock as of
September 30, 2002 was 6,000,000.

Registrant's common stock is listed on the OTC Bulletin Board under
the symbol "NVSL".

Transitional Small Business Disclosure Format:  Yes     No X


                                1
<PAGE>


                 Part I - Financial Information

Item 1.  Financial Statements

The interim financial statements for Novus Laboratories, Inc. (Company)
included herein are unaudited but reflect, in management's opinion, all
adjustments, consisting only of normal recurring adjustments, that are
necessary for a fair presentation of the Company's financial position
and the results of its operations for the interim periods presented.
Because of the nature of the Company's business, the results of
operations for the three and nine months ended September 30, 2002 are not
necessarily indicative of the results that may be expected for the full
fiscal year. The financial statements included herein should be read in
conjunction with the financial statements and notes thereto included in
the Form 10SB/A, filed June 27, 2002.



























                                2


<PAGE>











NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2002 AND 2001
Unaudited - See the Independent Review Engagement Report
---------------------------------------------------------------------









































------------------------------------------------------------------------------
                       Parker & Co., Chartered Accountants



                             3
<PAGE>



NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2002 AND 2001
Unaudited - See the Independent Review Engagement Report
-------------------------------------------------------------------------



C O N T E N T S


                                                                      Page
      		                                                   ------

INDEPENDENT REVIEW ENGAGEMENT REPORT                                   1


INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION                   2


INTERIM CONSOLIDATED STATEMENT OF LOSS AND DEFICIT                     3


INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS                           4


INTERIM CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY      5


NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS            6 TO 8


















------------------------------------------------------------------------------
                       Parker & Co., Chartered Accountants

                                  4
<PAGE>

P A R K E R  &  C O.                                 Page 1 of 8
CHARTERED ACCOUNTANTS
200 - 2560 Simpson Road, Richmond BC  V6X 2P9
Tel:  (604)  276-9920     Fax:  (604)  276-4577

INDEPENDENT REVIEW ENGAGEMENT REPORT

To the Board of Directors of Novus Laboratories, Inc.

We have reviewed the interim consolidated statement of financial
position of Novus Laboratories, Inc. as at 30 September 2002 and as at
31 December 2001 and the interim consolidated statements of results
of operations and cash flows for the three months and nine months
ended 30 September 2002 and 2001 and the interim consolidated statement
of changes in stockholders' equity from the date of incorporation
29 September 1998 to 30 September 2002, in accordance with the standards
established by the American Institute of Certified Public
Accountants. These interim consolidated financial statements are
the responsibility of the company's management.
A review of interim consolidated financial information consists
principally of obtaining an understanding of the system for the
preparation of interim consolidated financial information,
applying analytical review procedures to financial data, and
making inquiries of persons responsible for financial and
accounting matters. A review is substantially less in scope
than an audit in accordance with generally accepted auditing
standards, the objective of which is the expression of an
opinion regarding the financial statement taken as a whole.
Accordingly, we do not express such an opinion.	Based on our
review, we are not aware of any material modifications that
should be made to the interim consolidated financial statements
referred to above for them to be in conformity with generally
accepted accounting principles in the United States.
We have previously audited, in accordance with generally accepted
auditing standards in the United States, the consolidated statements
of financial position as at 31 December 2001, and the consolidated
statements of results of operation and cash flow for the year then
ended and the consolidated statement of changes in shareholders'
equity from inception, 29 September 1998, to 31 December 2001; and
in our report dated 17 March 2002, we expressed an unqualified
opinion on those consolidated financial statements. In our opinion,
the information set forth in the accompanying interim consolidated
statement of financial position as of 30 September 2002, is fairly
stated in all material respects in relation to the consolidated
statement of financial position from which it has been derived.
These interim consolidated financial statements have been prepared
assuming the company will continue as a going concern. As stated in
Note 2 to the interim consolidated financial statements, the company
will require an infusion of capital to sustain itself. This
requirement for additional capital raises substantial doubt about
the company's ability to continue as a going concern. The interim
consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.

Richmond, British Columbia, Canada
23 October 2002
/s/ PARKER & CO., CHARTERED ACCOUNTANTS

<TABLE><CAPTION>
NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
Unaudited - See the Independent Review Engagement Report
Page 2 of 8
------------------------------------------------------------------------------
                                                        AS AT            AS AT
                                                 30 SEPTEMBER      31 DECEMBER
                                                         2002             2001
                                                    ------------   -----------
<S>                                                      <C>             <C>

CURRENT ASSETS
Cash                                                  $       0     $       17
                                                    ------------   -----------
Total current assets                                          -             17
                                                    ------------   -----------
                                                    ------------   -----------

TOTAL ASSETS                                          $       0     $       17
                                                    ============   ===========

CURRENT LIABILITIES
Accounts payable                                      $   9,950     $    4,550
                                                    ------------   -----------
Total current liabilities                                 9,950          4,550
                                                    ------------   -----------

STOCKHOLDERS' EQUITY  (DEFICIENCY IN ASSETS)
Share capital, Note 3                                     6,000          6,000
Additional paid-in capital                               47,968         47,968
Deficit                                                 (63,918)       (58,501)
                                                    ------------   -----------
Total stockholders' equity (deficiency in assets)	 (9,950)        (4,533)
                                                    ------------   -----------

                                                    ------------   -----------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY          $      0       $       17
                                                    ============   ===========
</TABLE>




------------------------------------------------------------------------------
                       Parker & Co., Chartered Accountants

                                   5
<PAGE>



<TABLE><CAPTION>
NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
Unaudited - See the Independent Review Engagement Report           Page 3 of 8
------------------------------------------------------------------------------
                                 FOR THE THREE               FOR THE NINE
                                 MONTHS ENDED                MONTHS ENDED
                           --------------------------  -------------------------
                           30 SEPTEMBER 30 SEPTEMBER   30 SEPTEMBER 30 SEPTEMBER
                                   2002         2001           2002         2001
                           ------------ ------------   ------------ ------------
<S>                            <C>            <C>              <C>          <C>
REVENUE
Sales                      $         0  $          0   $          0  $        0
Interest earned                      -             -              -           -
                           -----------  ------------   ------------  ----------
Total revenue                        -             -              -           -
                           -----------  ------------   ------------  ----------

ABANDONED OPERATING
EXPENSES, NOTE 1
Bank charges                         -           (17)            17         123
Transfer agent fees                350             -            350           -
Professional fees                1,600           863          5,050       1,726
                          ------------  ------------   ------------  ----------
Total abandoned
operating expenses               1,950           846          5,417       1,849
                          ------------  ------------   ------------  ----------

LOSS                            (1,950)         (846)        (5,417)     (1,849)

INCOME TAXES, NOTE 4                 -             -              -           -
                          ------------  ------------   ------------  ----------
NET LOSS                        (1,950)         (846)        (5,417)     (1,849)
                          ============  ============   ============  ==========
LOSS PER SHARE, NOTE 5          ($0.00)       ($0.00)        ($0.00)	 ($0.00)
                          ============  ============   ============  ==========

WEIGHTED AVERAGE NUMBER
OF SHARES                    6,000,000     6,000,000      6,000,000   6,000,000
                          ============  ============   ============  ==========

DEFICIT, BEGINNING            ($61,968)     ($55,931)      ($58,501)   ($54,928)
Net loss                        (1,950)         (846)        (5,417)     (1,849)
                          ------------  ------------   ------------  ----------
DEFICIT, ENDING               ($63,918)     ($56,777)      ($63,918)   ($56,777)
                          ============  ============   ============  ==========
</TABLE>
------------------------------------------------------------------------------
                       Parker & Co., Chartered Accountants

                                 6
<PAGE>

<TABLE><CAPTION>
NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
Unaudited - See the Independent Review Engagement Report           Page 4 of 8
------------------------------------------------------------------------------
                                 FOR THE THREE               FOR THE NINE
                                 MONTHS ENDED                MONTHS ENDED
                           --------------------------  -------------------------
                           30 SEPTEMBER 30 SEPTEMBER   30 SEPTEMBER 30 SEPTEMBER
                                   2002         2001           2002         2001
                           ------------ ------------   ------------ ------------
<S>                            <C>            <C>              <C>          <C>
CASH PROVIDED (USED) FROM OPERATIONS
From operation
Net loss                        ($1,950)      ($846)       ($5,417)     ($1,849)
                           ------------ ------------   ------------ ------------

Changes in working capital
other than cash
  Accounts payable                1,950         863           5,400       1,726
                           ------------ ------------   ------------ ------------
Total changes in working
capital other than cash           1,950         863           5,400       1,726
                           ------------ ------------   ------------ ------------
Total cash provided (used)
from operations                       -          17             (17)       (123)
                           ------------ ------------   ------------ ------------

CASH PROVIDED (USED) BY
INVESTMENT ACTIVITY                   -           -               -           -
                           ------------ ------------   ------------ ------------
Total cash provided (used) by
investment activity                   -           -               -           -
                           ------------ ------------   ------------ ------------
CASH PROVIDED (USED) BY
FINANCING ACTIVITY
  Shares issued                       -           -               -           -
  Additional paid in capital          -           -               -           -
                           ------------ ------------   ------------ ------------
Total cash provided by
financing activities                  -           -               -           -
                           ------------ ------------   ------------ ------------
CASH CHANGE                           -          17             (17)       (123)
CASH BEGINNING                        -           -              17         140
                           ------------ ------------   ------------ ------------
CASH ENDING                $          0 $        17    $          0 $        17
                           ============ ============   ============ ============
COMPRISED OF:
Cash                       $          0 $        17    $          0 $        17
                           ============ ============   ============ ============
</TABLE>
------------------------------------------------------------------------------
                      Parker & Co., Chartered Accountants

                                       7
<PAGE>
<TABLE><CAPTION>
NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
FROM INCORPORATION, 29 SEPTEMBER 1998, TO 30 SEPTEMBER 2002
Unaudited - See the Independent Review Engagement Report          Page 5 of 8
------------------------------------------------------------------------------
                              COMMON   COMMON ADDITIONAL
                               STOCK    STOCK    PAID IN
CONSIDERATION                 ISSUED   AMOUNT    CAPITAL   DEFICIT      TOTAL
--------------------------  --------  -------- --------- --------- -----------
<S>                            <C>      <C>        <C>       <C>         <C>
Private placement for cash
Trading restrictions apply
Issued on 1 December 1998
Issue price was
$0.005 per share		   1,000,000  $  1,000  $  4,000        5,000

Net loss from 29 September
1998, date of incorporate,
to 31 December 1998                                        ($1,054)    (1,054)
                           ---------  -------- --------- --------- -----------
Balance 31 December 1998   1,000,000     1,000     4,000    (1,054)     3,946

Private placement for cash
No trading restrictions
Issued on 6 April 1999
Issue price was $0.05      1,000,000     1,000    49,000               50,000

Net loss for the year
ended 31 December 1999                                     (12,336)   (12,336)
                           ---------  -------- --------- --------- -----------
Balance 31 December 1999   2,000,000     2,000    53,000   (13,390)    41,610

Purchase of Novus
Laboratories, Inc. of Nevada
Trading restrictions apply
Issued on 11 May 2000      4,000,000     4,000    (5,032)              (1,032)

Stock split 3 for 1
Cancelled on 20 June 2000 (6,000,000)   (6,000)    6,000                    -
Reissued  on 20 June 2000  18,000,000    18,000  (18,000)                   -

Stock surrendered to
treasury Cancelled on
15 July 2000             (12,000,000)  (12,000)   12,000                    -

Net loss for the year
ended 31 December 2000                                     (41,538)   (41,538)
                          ---------  -------- --------- --------- -----------
Balance as at
31 December 2000           6,000,000     6,000    47,968   (54,928)      (960)


                                      9
<PAGE>




Net loss for the year
ended 31 December 2001                                      (3,573)    (3,573)
                           ---------  -------- --------- --------- -----------
Balance as at 31
December 2001              6,000,000     6,000    47,968   (58,501)    (4,533)

Net loss for the nine
months ended
30 September 2002                                           (5,417)    (5,417)
                           ---------  -------- --------- --------- -----------
Balance as at
30 September 2002          6,000,000     6,000    47,968   (63,918)    (9,950)
                           =========  ========  ========  =========  =========
</TABLE>





























------------------------------------------------------------------------------
                       Parker & Co., Chartered Accountants



                                       9(i)

<PAGE>

NOVUS LABORATORIES, INC.
(FORMERLY ASIA PACIFIC TRADING, INC., SEE NOTE 1)
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS AND NINE MONTHS ENDED 30 SEPTEMBER 2002 AND 2001
Unaudited - See the Independent Review Engagement Report  Page 6 of 8

Note 1  THE CORPORATION AND ITS SUBSIDIARY AND THEIR BUSINESS

Asia Pacific Trading, Inc. was incorporated in the State of Delaware,
United States of America on 29 September 1998. On 11 May 2000 Asia
Pacific Trading, Inc. merged with Novus Laboratories, Inc., a Nevada
incorporated company. The arrangements called for the assets of Novus
Laboratories, Inc. to be transferred to Asia Pacific Trading, Inc. and
then Novus Laboratories, Inc. of Nevada was to be wound up and
liquidated in exchange for 4,000,000 shares of the common stock of
Asia Pacific Trading, Inc. This wind up and liquidation was not
completed. In addition, Asia Pacific Trading, Inc. was to change its
name to Novus Laboratories, Inc., which it did on 20 June 2000. As a
result, Novus Laboratories, Inc. of Nevada became a subsidiary of the
Delaware parent company which has the same name as the Nevada
subsidiary company. The 4,000,000 shares of common stock of the
Delaware parent company were issued on 11 May 2000 in exchange for 100%
of the shares of the common stock of the Nevada subsidiary company. In
the month of July 2002 Novus Laboratories, Inc., the Nevada corporation
was dissolved.

The Nevada subsidiary company was incorporated in the State of Nevada
on 1 September 1999 and has a wholly owned Canadian subsidiary, Bella
Terra Cosmetics Inc. which was incorporated in the Province of British
Columbia, Canada on 1 November 1999. The 50 issued common shares of
Bella Terra Cosmetics, Inc. are held in trust by the president of the
company for its Nevada parent company. Bella Terra Cosmetics, Inc. has
been abandoned and its registration as a corporation is being allowed
to lapse.

The company has an office in Vancouver, British Columbia, Canada. The
company was organized to produce and sell pharmaceutical and cosmetic
skin care products. On the 31 December 2000 the company abandoned all
of its intellectual property right to the pharmaceutical and cosmetic
products because it was unable to obtain new financing to complete its
business plan.  The company has not yet established itself as a going
concern and will require new financing to sustain any new operations.
The fiscal year end of the company is 31 December.

Note 2  SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

These interim consolidated financial statements have been prepared in
United States dollars, which have been rounded to the nearest whole
dollar except for the net loss per share which has been rounded to
the nearest cent, using United States of America Generally Accepted
Accounting Principles. These accounting principles are applicable to a
going concern, which contemplates the realization and liquidation of
liabilities in the normal course of business. Current business activity
have been abandoned and insufficient revenue has been generated to
sustain the company as a going concern without the infusion of
additional capital.

The merger of the subsidiary was accounted for as a purchase. The
assets less the liabilities were valued at fair market value which
equaled the price consideration. Only revenue, expenses and cash
flow since the acquisition have been included in the interim
consolidated financial statements.

The Canadian dollar financial statements of the subsidiary's subsidiary
were translated into United States of America dollars during
consolidation using the exchange rate at the end of the year for all
monetary assets and liabilities. Non monetary assets and liabilities
are translated using the historical exchange rate at the time the asset
or liability was acquired. Revenue and expenses are translated at the
exchange rate at the time the transaction was recorded. The deficit was
translated at its historical rate.

Revenue is recorded as a sale at the time the goods are shipped from
the company's warehouse. Costs are recorded at the time an obligation
to pay occurs and are expensed at the time the benefit to the company
is matched to revenue or, if there is no matching revenue, to the
period in which the benefit is realized.

Note 3   SHARE CAPITAL

The authorized capital stock is 25,000,000 shares of common stock with
a par value of $0.001. In conjunction with a 3 for 1 stock split on
20 June 2000 the authorized capital stock of 25,000,000 shares of
common stock with a par value of $0.001 was cancelled and reauthorized
as 25,000,000 shares of common stock with a par value of $0.001.
6,000,000 shares of common stock have been issued as follows:
<TABLE><CAPTION>
                                                              ADDITIONAL
                                                      SHARE     PAID IN
CONSIDERATION                   DATE       ISSUED   CAPITAL     CAPITAL	  TOTAL
-------------------------- --------------- -------  ---------  --------- -------
<S>                            <C>            <C>     <C>          <C>      <C>
Private placement for cash
Trading restrictions apply 1 December 1998 1,000,000  $ 1,000  $  4,000  $ 5,000

Private placement for cash
No trading restrictions
Issued price was $0.05     2 September 1999 1,000,000   1,000    49,000   50,000

Novus Laboratories, Inc.
purchased Trading
restrictions apply              11 May 2000  4,000,000   4,000   (5,032) (1,032)

Stock split 3 for 1
Cancelled                      20 June 2000 (6,000,000) (6,000)   6,000
Reissued                       20 June 2000 18,000,000  18,000  (18,000)



Stock surrendered to
treasury Cancelled             15 July 2000 (12,000,000)(12,000)  12,000
                                            ----------- -------- -------- -------
Balance as at            30 September 2002    6,000,000 $ 6,000  $47,968 $53,968
                                            =========== ======== ======== =======
</TABLE>

The company has issued 6,000,000 common shares. 3,000,000 of these
shares are "control securities" which cannot be sold except pursuant
to certain limitations and restrictions.

Note 4   INCOME TAXES

Income taxes on losses have not been reflected in these interim
consolidated financial statements as it is not virtually certain that
these losses will be recovered before the expiry period of the loss
carry forwards.

Note 5   LOSS PER SHARE

Basic loss per share is computed by dividing the loss available to
common stockholders by the weighted-average number of common shares
during the period. Diluted loss per share is computed by dividing the
loss after dilative common stock equivalents amounts have been
converted to common stock. No stock options were available or granted
during the period presented. Accordingly, basic and diluted loss per
share are the same for all periods presented.

Note 6  RELATED PARTY TRANSACTIONS

The company neither owns nor leases any real property. Office services
are provided by the president of the company. Such costs are immaterial
to the interim consolidated financial statements and accordingly have
not been reflected therein. The officers and directors of the company
are involved in other business activities, and may, in the future become
active in additional other business activities. If a specific business
opportunity becomes available, such persons may face a conflict in
selecting between the company and their own business interests. The
company has not formulated a policy for the resolution of such conflicts.













                              13

<PAGE>

Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations

Plan of Operation
-----------------
For the period from inception to the nine months ended September 30,
2000, Registrant had not yet generated any revenues or expended any
significant amount of money for research and development. During the
next 12 months, Registrant does not intend to purchase any
significant property or equipment.

Results of Operations
---------------------
For the nine months ended September 30, 2002, Registrant had no
revenues and incurred net operating losses of $5,417, all of which
comprised abandoned operating expenses.


 	              PART II - OTHER INFORMATION

ITEM 6.	EXHIBITS AND REPORTS OF FORM 8-K

A)  The following exhibits marked with an asterisk, which are
required to be filed herein are incorporated by reference and
can be found in their entirety in Registrant's Form 10-SB,
filed with the Commission on June 28, 2002.

Exhibit No.     Description
-----------     -----------
 3(i) *         Articles of Incorporation
 3(ii) *        Bylaws
99              Certifications Pursuant to Sec. 906

B) There were no reports on Form 8-K filed during the quarter.



                          SIGNATURES
                          ----------
In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                             Novus Laboratories, Inc.
                            ------------------------
Dated: November 11, 2002     By:/s/ James Markovitch,
                             President, Secretary, Treasurer,
                             CEO, CFO and Director


                                14
<PAGE>


         CERTIFICATION PURSUANT TO SECTION 302
         -------------------------------------

   I, James Markovitch, certify that:

1.  I have reviewed this quarterly report on Form 10-QSB of Novus
Laboratories, Inc.

2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect
to the period covered by this quarterly report.

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of Novus Laboratories, Inc. as of, and for, the periods
presented in this quarterly report.

4.  Novus Laboratories, Inc.'s other certifying officers and I are
responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
Novus Laboratories, Inc. and have:

     (a) designed such disclosure controls and procedures to
     ensure that material information relating to Novus
     Laboratories, Inc., including its consolidated subsidiaries,
     is made known to us by others within those entities,
     particularly during the period in which this quarterly
     report is being prepared;

     (b) evaluated the effectiveness of Novus Laboratories, Inc.
     disclosure controls and procedures as of a date within
     90 days prior to the filing date of this quarterly report
     (the "Evaluation Date"); and

     (c) presented in this quarterly report our conclusions
     about the effectiveness of the disclosure controls and
     procedures based on our evaluation as of the Evaluation Date;

5.  The other certifying officers and I have disclosed, based on our
most recent evaluation, to our auditors and the audit committee of our
Board of Directors (or persons performing the equivalent functions):

   (a)	all significant deficiencies in the design or operation of
   internal controls which could adversely affect our ability to
   record, process, summarize and report financial data and have
   identified for our auditors any material weaknesses in internal
   controls; and



                             15
<PAGE>








   (b)	any fraud, whether or not material, that involves management
   or other employees who have a significant role in our internal
   controls.

6. The other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal
controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies
and material weaknesses.



   November 11, 2002      	/s/ James Markovitch
                              ----------------------------------------
			      James Markovitch, Chief Executive Officer,
                              Chief Financial Officer and Chairman of
                              the Board of Directors


























                                16
<PAGE>